Mast Flags Offering's $22.9M for Sickle Cell Phase III Trial
By Randy Osborne
Friday, June 14, 2013
Mast Therapeutics Inc.'s $22.9 million from a public offering will fund the second Phase III trial with the sickle cell disease candidate MST-188, a purified form of a nonionic, triblock copolymer (poloxamer 188) that was first developed for the treatment of heart attacks.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.